Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Poteligeo, Mogamulizumab, Sezary Syndrome,Mycosis Fungoides, Date of Authorisation: 22/11/2018, Status: Authorised
Case Medical Research
doi 10.31525/cmr-9e21cd
Full Text
Open PDF
Abstract
Available in
full text
Date
January 28, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): PritorPlus, Telmisartan / Hydrochlorothiazide, Hypertension, Date of Authorisation: 22/04/2002, Revision: 33, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Levetiracetam Sun, Levetiracetam, Epilepsy, Date of Authorisation: 14/12/2011, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Tadalafil Mylan, Tadalafil, Erectile Dysfunction, Date of Authorisation: 21/11/2014, Revision: 8, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Betmiga, Mirabegron, Urinary Bladder, Overactive, Date of Authorisation: 20/12/2012, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Macimorelin Aeterna Zentaris, Macimorelin, Diagnostic Techniques, Endocrine, Date of Authorisation: 11/01/2019, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Olazax, Olanzapine, Schizophrenia,Bipolar Disorder, Date of Authorisation: 11/12/2009, Revision: 10, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Mysimba, Naltrexone / Bupropion, Obesity,Overweight, Date of Authorisation: 26/03/2015, Revision: 11, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Aripiprazole Accord, Aripiprazole, Schizophrenia,Bipolar Disorder, Date of Authorisation: 15/11/2015, Revision: 6, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Silodosin Recordati, Silodosin, Prostatic Hyperplasia, Date of Authorisation: 07/01/2019, Status: Authorised
Case Medical Research
